STRATEC Biomedical (ETR:SBS) stock price target increased to 47.00EUR, issued a report today by HSBC
- Updated: November 26, 2016
In a report released on 11/27/2016 HSBC increased the stock price target of STRATEC Biomedical (ETR:SBS) to 47.00EUR indicating a possible upside of 0.11%.
Previously on Saturday November 26, 2016, HSBC reported on STRATEC Biomedical (ETR:SBS) increased the target price from 0.00EUR to 47.00EUR. At the time, this indicated a possible upside of 0.11%.
Yesterday STRATEC Biomedical (ETR:SBS) traded -0.92% lower at 42.42EUR. The company’s 50-day moving average is 9.53EUR and its 200-day moving average is 8.91EUR. The last closing price is up -3.48% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 773,048 shares of the stock traded hands, down from an average trading volume of 1,707,990
See Chart Below
STRATEC Biomedical has a PE ratio of 8.25 with a one year low of 3.98EUR and a one year high of 10.55EUR SBS’s total market value is presently 0 EUR.
A total of 3 firms have issued a report on the stock. 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 brokers rating the stock a hold, 0 analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of 28.48EUR.
General Company Details For STRATEC Biomedical (ETR:SBS)
STRATEC Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. STRATEC Group operats through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.